In Section C, contributors will receive ABBV-744 and oral navitoclax. In Section D, individuals will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally sickness progression or maybe the contributors are unable to tolerate the study drugs. 88 These preclinical studies present paradigms for potential clinical trials in AML, https://johna221myi4.ageeksblog.com/profile